<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012621</url>
  </required_header>
  <id_info>
    <org_study_id>13-2104</org_study_id>
    <nct_id>NCT02012621</nct_id>
  </id_info>
  <brief_title>Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy</brief_title>
  <acronym>2104</acronym>
  <official_title>Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate cumulative exposure to tenofovir diphosphate
      (TFV-DP) using dried blood spots (DBS) in treated HIV-infected patients who are receiving a
      TFV-based regimen. Using DBS will allow the investigators to assess this simple method to
      measure drug exposure in the clinical setting. The investigators hypothesize that TFV-DP
      levels will be lowest in individuals with a detectable viral load and highest in those with
      viral suppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral drug exposure is directly linked to individual host factors which include age,
      weight, diet, and genetics. However, the main factor impacting long-term drug exposure is
      drug adherence. Adherence is a strong predictor of HIV treatment outcomes, but measuring
      adherence is difficult due to the inaccuracy of self-reporting and other commonly used
      monitoring methods. To date, no gold standard measure to monitor antiretroviral exposure and
      adherence has been applied in clinical practice. Tenofovir (TFV) and its active metabolite,
      tenofovir diphosphate (TFV-DP), have distinctive pharmacological characteristics that make
      them ideal candidates for drug adherence and exposure monitoring. The long half life (~14-17
      days) of TFV-DP in red blood cells (RBC) are properties well suited for monitoring average
      dose exposure over time. Based on these, the investigators propose that RBC levels of TFV-DP
      are an accurate and precise measure of long-term drug exposure in HIV-infected individuals.
      In addition, the investigators aim to quantify TFV-DP in dried blood spots (DBS) as a simple
      method to measure drug exposure.

      This is an observational, 48-week prospective study of HIV-infected individuals treated with
      TFV in which the investigators will compare DBS TFV-DP levels in virologically suppressed vs.
      non-suppressed individuals and evaluate the utility of TFV-DP in DBS to predict virologic
      failure and also drug toxicity. To accomplish this, the investigators will approach
      HIV-infected patients currently taking TFV (which is being prescribed by a primary care
      physician) and who present to the clinic for regular HIV care. After informed consent is
      obtained, the investigators will collect extra blood samples for DBS TFV-DP and obtain
      information on drug adherence. The investigators will also collect extra blood samples for
      DBS TFV-DP at each subject's subsequent visit for approximately 3 visits in a 48 week period
      of time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at All Study Visits</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); reference group: drug concentration (TFV-DP) &lt; 350 femtomole (fmol)/punch vs. drug concentration (TFV-DP) &gt;= 1850 fmol/punch; adjusted odds ratio calculated using generalized estimating equations; concentration cutoffs established in prior research of healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Odds Ratio of Three-month Self-reported Adeherence Associated With Odds of HIV Viral Suppression at All Study Visits</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); reference group: three-month self-reported adherence &lt;28.5% vs. three-month self-reported adherence 100%; adherence cutoffs established in prior research</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at Next Study Visit</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); drug concentration (TFV-DP) &lt;800 femtomole (fmol)/punch) vs reference group of drug concentration (TFV-DP) &gt;= 1650 fmol/punch; adjusted odds ratio calculated using generalized estimating equations</description>
  </primary_outcome>
  <enrollment type="Actual">807</enrollment>
  <condition>HIV/AIDS</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected individuals who are taking tenofovir.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected individual.

          -  18 years and older.

          -  Taking tenofovir.

          -  Blood drawn during regular clinic visit.

        Exclusion Criteria:

          -  Refusal to participate.

          -  Pregnancy.

          -  Inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose R. Castillo-Mancilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado - Anschutz Medical Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado-Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>October 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Adherence</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Dried Blood Spots</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02012621/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Cohort</title>
          <description>807 persons living with HIV (PLWH) on tenofovir disoproxil fumarate (TDF) at baseline were followed for up to three visits or 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="807"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 1 Completed</title>
              <participants_list>
                <participants group_id="P1" count="807"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2 Completed</title>
              <participants_list>
                <participants group_id="P1" count="688"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 3 Completed</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="807"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>TFV-DP concentrations in DBS were available from 532 participants over three visits or 48 weeks. TFV-DP concentrations in DBS were available from 521 participants at baseline. Demographics from the full cohort (N=807) are reported here.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Cohort</title>
          <description>807 persons living with HIV (PLWH) on tenofovir disoproxil fumarate (TDF) at baseline were followed for up to three visits or 48 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="807"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="37" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="472"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at All Study Visits</title>
        <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); reference group: drug concentration (TFV-DP) &lt; 350 femtomole (fmol)/punch vs. drug concentration (TFV-DP) &gt;= 1850 fmol/punch; adjusted odds ratio calculated using generalized estimating equations; concentration cutoffs established in prior research of healthy volunteers</description>
        <time_frame>Up to 48 Weeks</time_frame>
        <population>Drug concentrations were available from 532 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>807 persons living with HIV (PLWH) on tenofovir disoproxil fumarate (TDF) at baseline were followed for up to three visits or 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at All Study Visits</title>
          <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); reference group: drug concentration (TFV-DP) &lt; 350 femtomole (fmol)/punch vs. drug concentration (TFV-DP) &gt;= 1850 fmol/punch; adjusted odds ratio calculated using generalized estimating equations; concentration cutoffs established in prior research of healthy volunteers</description>
          <population>Drug concentrations were available from 532 participants</population>
          <units>Adjusted odds ratio (aOR)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="25.7" upper_limit="210.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>73.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.7</ci_lower_limit>
            <ci_upper_limit>210.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Odds Ratio of Three-month Self-reported Adeherence Associated With Odds of HIV Viral Suppression at All Study Visits</title>
        <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); reference group: three-month self-reported adherence &lt;28.5% vs. three-month self-reported adherence 100%; adherence cutoffs established in prior research</description>
        <time_frame>Up to 48 Weeks</time_frame>
        <population>Three-month self-reported adherence data were available from 482 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>807 persons living with HIV (PLWH) on tenofovir disoproxil fumarate (TDF) at baseline were followed for up to three visits or 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Odds Ratio of Three-month Self-reported Adeherence Associated With Odds of HIV Viral Suppression at All Study Visits</title>
          <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); reference group: three-month self-reported adherence &lt;28.5% vs. three-month self-reported adherence 100%; adherence cutoffs established in prior research</description>
          <population>Three-month self-reported adherence data were available from 482 participants</population>
          <units>Adjusted odds ratio (aOR)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.3" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>30.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at Next Study Visit</title>
        <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); drug concentration (TFV-DP) &lt;800 femtomole (fmol)/punch) vs reference group of drug concentration (TFV-DP) &gt;= 1650 fmol/punch; adjusted odds ratio calculated using generalized estimating equations</description>
        <time_frame>Up to 48 Weeks</time_frame>
        <population>Paired drug concentration (TFV-DP) and HIV VL assessments were available from 451 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>807 persons living with HIV (PLWH) on tenofovir disoproxil fumarate (TDF) at baseline were followed for up to three visits or 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at Next Study Visit</title>
          <description>HIV viral load, binary cutoff at assay level of detection (&lt;20 copies/mL vs. &gt;= 20 copies/mL); drug concentration (TFV-DP) &lt;800 femtomole (fmol)/punch) vs reference group of drug concentration (TFV-DP) &gt;= 1650 fmol/punch; adjusted odds ratio calculated using generalized estimating equations</description>
          <population>Paired drug concentration (TFV-DP) and HIV VL assessments were available from 451 participants</population>
          <units>Adjusted odds ratio (aOR)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.6" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>N/A: observational study where samples were collected at the time of normally scheduled clinic visits</time_frame>
      <desc>N/A: observational study where samples were collected at the time of normally scheduled clinic visits; AEs not assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Cohort</title>
          <description>807 persons living with HIV (PLWH) on tenofovir disoproxil fumarate (TDF) at baseline were followed for up to three visits or 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jose Castillo-Mancilla</name_or_title>
      <organization>University of Colorado-AMC</organization>
      <phone>303-724-4934</phone>
      <email>jose.castillo-mancilla@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

